| Prev Close | 21.20 |
| Day Low/High | 20.84 / 21.40 |
| 52 Wk Low/High | 20.12 / 58.72 |
ACADIA Pharmaceuticals Inc. (ACAD)
21.15
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 160.05B |
| Market Cap | 3.39B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Acadia Pharmaceuticals: a Tough Pill to Swallow
A long repair process will be needed in the months ahead. Let's check the charts.
An All-Terrain Strategy for Portfolio Management
The market's mood seems to be changing almost daily; he's an approach for how to trade it regardless of how it's feeling on any particular day.
Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week
These names are displaying both technical and quantitative deterioration.
Indices Look Susceptible to a Pullback, and a Way to Play a Dinged Biopharma
Various hard-charging mega-cap stocks seem overdue for a significant pause, while a drop in Acadia Pharmaceuticals sets up an options play.
3 Promising Biotech Stocks to Buy on a Market Pullback
Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.
Fishing in 2 More Ponds Where Insiders Are Buying
Acadia Pharmaceuticals and HD Supply each have seen significant insider purchases of late.
The Wisdom of Taking Profits in Small Biotech Stocks Upon FDA Drug Approval
There are multiple reasons why these stocks often decline after their drugs receive the blessing of regulators.
The Big Challenge: Putting Idle Capital to Work Without Chasing Too Much
There isn't much choice but to buy strength.
6 Top Biopharmaceutical Stock Picks You Should Know About
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Positive Developments for These 3 Biotech Stocks
We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.
2 Attractive Biotechs With Key Study Outcomes on the Horizon
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks
Quick takes on fourth-quarter results from these 3 biotech names.
8 Stocks Poised to Change Direction
These names are showing technical characteristics of either bullish or bearish reversal patterns.
3 Biotech Best Bets From the 'Stock Picker of the Year'
In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.
Time to Marinate the Ice Cubes
Great being here on Daily Diary today. Nice to see a huge rally for once standing in for Dougie as well. Lots of good conversation as the markets close near their highs for the day. Some big moves in the small biotech names that are near and dear to...
A Rash of Biotech News
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...
3 Good Bargain Stocks With Insider Buying
I continue to keep a 'shopping list' at the ready for the next dip in the market.
Multiple Creep... and More
Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...
These 2 Biotech Stocks Still Have Upside
The biotech sector has seen a big rally, but there are still opportunities.
Acadia, Dynavax Make the Biotech Mailbag
Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.
The Good, the Bad and the Ugly (Monday Edition)
"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: "The Good, the Bad and the Ugly" There was plenty of sector rotation today (but little overall movement), so let's move to the abbreviated Monarch Notes form of "Takeaw...
Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers
The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
Biotech M&A: Who's Next After Gilead-Kite?
Prospects for acquisition activity in the sector are improving.
'Longing' for Acadia Pharmaceuticals? Here's How to Play It
ACAD looks strong enough for a rally at least to the upper $30s.
